While Aquestive Therapeutics Inc has underperformed by -1.64%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AQST rose by 88.95%, with highs and lows ranging from $6.23 to $1.84, whereas the simple moving average fell by -10.73% in the last 200 days.
On December 17, 2024, Cantor Fitzgerald started tracking Aquestive Therapeutics Inc (NASDAQ: AQST) recommending Overweight. A report published by Leerink Partners on May 10, 2024, Initiated its previous ‘Outperform’ rating for AQST. Piper Sandler also rated AQST shares as ‘Overweight’, setting a target price of $10 on the company’s shares in an initiating report dated April 11, 2024. Raymond James Initiated an Outperform rating on March 28, 2024, and assigned a price target of $7. RBC Capital Mkts initiated its ‘Outperform’ rating for AQST, as published in its report on April 07, 2021. Lake Street also rated the stock as ‘Buy’.
Analysis of Aquestive Therapeutics Inc (AQST)
Further, the quarter-over-quarter increase in sales is 4.15%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Aquestive Therapeutics Inc’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 5.91, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and AQST is recording an average volume of 1.51M. On a monthly basis, the volatility of the stock is set at 6.42%, whereas on a weekly basis, it is put at 7.90%, with a loss of -0.28% over the past seven days. Furthermore, long-term investors anticipate a median target price of $10.83, showing growth from the present price of $3.59, which can serve as yet another indication of whether AQST is worth investing in or should be passed over.
How Do You Analyze Aquestive Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 14.88%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 45.89% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AQST shares are owned by institutional investors to the tune of 45.89% at present.
